gene

IL10

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about IL10: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

587Connections

0Hypotheses

2Analyses

50Outgoing

50Incoming

Summary

IL10 is a gene implicated in neurodegeneration research. Key relationships include: therapeutic target, associated with, expressed in. Associated with ALS, Als, Atherosclerosis. Connected to 210 entities in the SciDEX knowledge graph.

View on Wiki →

🧬 Gene Info

Gene Symbol	IL10
Full Name	IL10 — Interleukin 10
Chromosome	1q31.3
Protein Type	Ligand
Target Class	Ligand
Function	Recombinant protein replacement or monoclonal antibody modulation
Mechanism of Action	Recombinant protein replacement or monoclonal antibody modulation
Druggability	Low (0.36)
Clinical Stage	Phase II
Amino Acids	160 aa
Exons	5
Pathways	JAK-STAT pathway
UniProt ID	Q6FGW4
NCBI Gene ID	3586
GeneCards	IL10
Human Protein Atlas	IL10
Associated Diseases	ALS, Alzheimer, Alzheimer's disease, Crohn'S Disease, Hypertension
Known Drugs/Compounds	Viral Therapeutic Approach
Interactions	AHR, TGFB1, ATG16L1, LC3, IL18, TNF
SciDEX Target	View Target Profile (8 clinical trials)
KG Connections	587 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: IL10 — AlphaFold Q6FGW4 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    IL10["IL10"]
    IL10 -->|"activates"| osteoblastogenesis["osteoblastogenesis"]
    IL10 -->|"inhibits"| NEUROINFLAMMATION["NEUROINFLAMMATION"]
    IL10 -->|"inhibits"| Fibrosis["Fibrosis"]
    IL10 -->|"target for"| Ms["Ms"]
    IL10 -->|"target for"| Hepatitis["Hepatitis"]
    IL10 -->|"target for"| Carcinoma["Carcinoma"]
    IL10 -->|"target for"| Cancer["Cancer"]
    IL10 -->|"target for"| Als["Als"]
    IL10 -->|"target for"| Inflammation["Inflammation"]
    h_f9c6fa3f["h-f9c6fa3f"] -->|"target for"| IL10
    MICROGLIA["MICROGLIA"] -->|"expressed in"| IL10
    FGF20["FGF20"] -->|"target for"| IL10
    BRG1["BRG1"] -->|"target for"| IL10
    NRCAM["NRCAM"] -->|"target for"| IL10
    NOTCH2["NOTCH2"] -->|"target for"| IL10
    EP300["EP300"] -->|"target for"| IL10
    CTNNB1["CTNNB1"] -->|"target for"| IL10
    NEUROD1["NEUROD1"] -->|"target for"| IL10

Outgoing (362)

Target	Relation	Type	Str
Sphingolipid Metabolism	inhibits	pathway	0.95
Immune Cell Activation	inhibits	process	0.95
Cytokine Production	inhibits	process	0.95
osteoblastogenesis	activates	pathway	0.90
M2 Microglia Phenotype	upregulates	phenotype	0.90
Microglia Polarization	modulates	process	0.90
very long chain ceramides	suppresses	compound	0.90
Neuroinflammation	inhibits	process	0.90
SPHINGOLIPID METABOLISM	inhibits	entity	0.90
Inflammatory Bowel Disease	protects_against	disease	0.90
Neuroinflammation	treats	disease	0.90
Inflammation	inhibits	process	0.88
Dopaminergic Neuron Loss	protects_against	phenotype	0.85
Anti-Inflammatory Response	mediates	process	0.85
Sphingolipid Metabolism	regulates	pathway	0.85
Crohn'S Disease	associated_with	disease	0.85
innate immune cells	modulates	cell_type	0.85
Crohn's Disease	risk_factor_for	disease	0.85
Immune Response	inhibits	process	0.85
motor recovery	promotes	phenotype	0.80
Parkinson's Disease	treats	disease	0.80
MACROPHAGE	regulates	entity	0.80
MICROGLIA	regulates	entity	0.80
Atherosclerosis	inhibits	disease	0.80
Als	associated_with	disease	0.75
Cancer	therapeutic_target	disease	0.75
NEUROINFLAMMATION	inhibits	phenotype	0.72
Immune Response	involved_in	process	0.70
MYD88	regulates	gene	0.65
Ms	associated_with	disease	0.65
Fibrosis	inhibits	disease	0.65
Ms	therapeutic_target	disease	0.65
Fibrosis	therapeutic_target	disease	0.65
Hepatitis	therapeutic_target	disease	0.65
Carcinoma	therapeutic_target	disease	0.65
Als	therapeutic_target	disease	0.65
Inflammation	therapeutic_target	disease	0.65
Als	activates	disease	0.65
Atherosclerosis	therapeutic_target	disease	0.65
Hypertension	associated_with	disease	0.65
Obesity	expressed_in	disease	0.65
Depression	expressed_in	disease	0.65
Ms	expressed_in	disease	0.65
Epilepsy	activates	disease	0.65
Ms	activates	disease	0.65
ALS	associated_with	disease	0.65
Inflammation	associated_with	disease	0.65
Prostate Cancer	therapeutic_target	disease	0.65
Infection	therapeutic_target	disease	0.65
Hepatocellular Carcinoma	therapeutic_target	disease	0.65

Incoming (225)

Source	Relation	Type	Str
Betulinic Acid	upregulates	compound	0.90
Lipid Nanoparticle	transports	compound	0.90
Mbdnf@Αitgev	upregulates	compound	0.90
Microglia	expressed_in	cell_type	0.90
h-f9c6fa3f	targets_gene	hypothesis	0.90
Viral Therapeutic Approach	targets	drug	0.85
CD22 Blockade	upregulates	drug	0.85
Ginsenoside Ro	upregulates	compound	0.85
RU486	upregulates	drug	0.85
h-f9c6fa3f	targets	hypothesis	0.80
GINSENOSIDE_RO	upregulates	compound	0.80
mesenchymal stem cell	associated_with	cell_type	0.75
TGFB1	associated_with	gene	0.70
TNF	associated_with	gene	0.70
JUN	associated_with	gene	0.70
GENES	associated_with	gene	0.70
GENES	therapeutic_target	gene	0.70
NOS2	activates	gene	0.65
MICROGLIA	expressed_in	cell_type	0.64
TYK2	associated_with	gene	0.60
DNMT3A	associated_with	gene	0.60
SMAD3	associated_with	gene	0.60
FGF20	therapeutic_target	gene	0.60
BRG1	therapeutic_target	gene	0.60
NRCAM	therapeutic_target	gene	0.60
NOTCH2	therapeutic_target	gene	0.60
EP300	therapeutic_target	gene	0.60
CTNNB1	therapeutic_target	gene	0.60
NEUROD1	therapeutic_target	gene	0.60
MYC	therapeutic_target	gene	0.60
VEGFA	therapeutic_target	gene	0.60
ABCB1	therapeutic_target	gene	0.60
FOXM1	therapeutic_target	gene	0.60
LEF1	therapeutic_target	gene	0.60
SMARCA4	therapeutic_target	gene	0.60
TERT	therapeutic_target	gene	0.60
FZD7	therapeutic_target	gene	0.60
JAG1	therapeutic_target	gene	0.60
MITF	therapeutic_target	gene	0.60
GAIN	therapeutic_target	gene	0.60
AXIN2	therapeutic_target	gene	0.60
CD44	therapeutic_target	gene	0.60
ALDH1A1	therapeutic_target	gene	0.60
FGF18	therapeutic_target	gene	0.60
ATF3	therapeutic_target	gene	0.60
BCL2	associated_with	gene	0.60
TP53	associated_with	gene	0.60
IL1B	associated_with	gene	0.60
PTGS2	associated_with	gene	0.60
MYC	associated_with	gene	0.60

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (2)

Scientific analyses that reference this entity

Digital biomarkers and AI-driven early detection of neurodegeneration

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.605

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

neurodegeneration | 2026-04-01 | 20 hypotheses Top: 0.617

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

IL10

Understanding Entity Pages

Summary

Wiki Pages (21)

IL10 — Interleukin 10

Creatine for Neuroprotection

CD200R1 Gene

move-brain-pd-nct07299279

Microbiome Metabolomics and SCFA Therapy for CBS/PSP

IL-10 Protein

Neuroinflammatory Cytokine Storm in Neurodegeneration

Neuroprotective Microglia

MITF Gene — Microphthalmia-Associated Transcription Factor

Epigenetic Biomarkers in Neurodegenerative Diseases

Section 123: Microbiome-Gut-Brain Axis Interventions for CBS/PSP

iPSC-Derived Neurons for Drug Screening in CBS/PSP

CD200 Gene

NfL-Guided Neuroprotection Threshold

Dental Health and Oral Microbiome in Parkinson's Disease

IL-6R Protein

NRF2 Activators in Neurodegenerative Disease

Hormone Neuroprotection in CBS/PSP

IL19 Gene

AhR Modulator Therapy for Neurodegenerative Diseases

Intermediate Progenitor Cells